Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 7-8/2021

03.02.2021 | original article

Methylprednisolone in adults hospitalized with COVID-19 pneumonia

An open-label randomized trial (GLUCOCOVID)

verfasst von: Luis Corral-Gudino, Alberto Bahamonde, Francisco Arnaiz-Revillas, Julia Gómez-Barquero, Jesica Abadía-Otero, Carmen García-Ibarbia, Víctor Mora, Ana Cerezo-Hernández, José L. Hernández, Graciela López-Muñíz, Fernando Hernández-Blanco, Jose M. Cifrián, Jose M. Olmos, Miguel Carrascosa, Luis Nieto, María Carmen Fariñas, José A. Riancho, GLUCOCOVID investigators

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 7-8/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Purpose

To determine whether a 6-day course of methylprednisolone (MP) improves outcome in patients with severe SARS-CoV‑2 (Corona Virus Disease 2019 [COVID-19]).

Methods

The study was a multicentric open-label trial of COVID-19 patients who were aged ≥ 18 years, receiving oxygen without mechanical ventilation, and with evidence of systemic inflammatory response who were assigned to standard of care (SOC) or SOC plus intravenous MP (40 mg bid for 3 days followed by 20 mg bid for 3 days). The primary outcome was a composite of death, admission to the intensive care unit, or requirement for noninvasive ventilation. Both intention-to-treat (ITT) and per protocol (PP) analyses were performed.

Results

A total of 91 patients were screened, and 64 were randomized (mean age70 ± 12 years). In the ITT analysis, 14 of 29 patients (48%) in the SOC group and 14 of 35 (40%) in the MP group suffered the composite endpoint (40% versus 20% in patients under 72 years and 67% versus 48% in those over 72 years; p = 0.25). In the PP analysis, patients on MP had a significantly lower risk of experiencing the composite endpoint (age-adjusted risk ratio 0.42; 95% confidence interval, CI 0.20–0.89; p = 0.043).

Conclusion

The planned sample size was not achieved, and our results should therefore be interpreted with caution. The use of MP had no significant effect on the primary endpoint in ITT analysis; however, the PP analysis showed a beneficial effect due to MP, which consistent with other published trials support the use of glucocorticoids in severe cases of COVID-19.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–5. CrossRef Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–5. CrossRef
3.
Zurück zum Zitat Guan W‑J, Ni Z‑Y, Hu Y, Liang W‑H, Ou C‑Q, He J‑X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708–20. CrossRef Guan W‑J, Ni Z‑Y, Hu Y, Liang W‑H, Ou C‑Q, He J‑X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708–20. CrossRef
5.
Zurück zum Zitat Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–4. CrossRef Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–4. CrossRef
6.
Zurück zum Zitat Siddiqi H, Mehra M. COVID-19 illness in native and Immunosuppresed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405–7. CrossRef Siddiqi H, Mehra M. COVID-19 illness in native and Immunosuppresed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405–7. CrossRef
7.
Zurück zum Zitat McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including Interleukin‑6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19:102537. CrossRef McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including Interleukin‑6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19:102537. CrossRef
8.
Zurück zum Zitat Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62. CrossRef Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62. CrossRef
9.
Zurück zum Zitat Cobos-Siles M, Cubero-Morais P, Arroyo-Jiménez I, Rey-Hernández M, Hernández-Gómez L, Vargas-Parra DJ, et al. Cause-specific death in hospitalized individuals infected with SARS-CoV-2: more than just acute respiratory failure or thromboembolic events. Intern Emerg Med. 2020;15:1533–44. https://​doi.​org/​10.​1007/​s11739-020-02485-y. Cobos-Siles M, Cubero-Morais P, Arroyo-Jiménez I, Rey-Hernández M, Hernández-Gómez L, Vargas-Parra DJ, et al. Cause-specific death in hospitalized individuals infected with SARS-CoV-2: more than just acute respiratory failure or thromboembolic events. Intern Emerg Med. 2020;15:1533–44. https://​doi.​org/​10.​1007/​s11739-020-02485-y.
10.
Zurück zum Zitat Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8:267–76. CrossRef Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8:267–76. CrossRef
11.
Zurück zum Zitat Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5:18. CrossRef Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5:18. CrossRef
13.
Zurück zum Zitat Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212:416–20. CrossRef Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212:416–20. CrossRef
15.
Zurück zum Zitat Ling Y, Xu S‑B, Lin Y‑X, Tian D, Zhu Z‑Q, Dai F‑H, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J. 2020;133:1039–43. CrossRef Ling Y, Xu S‑B, Lin Y‑X, Tian D, Zhu Z‑Q, Dai F‑H, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J. 2020;133:1039–43. CrossRef
16.
Zurück zum Zitat Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343. CrossRef Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343. CrossRef
18.
Zurück zum Zitat Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the coDEX randomized clinical trial. JAMA. 2020;324:1307–16. https://​doi.​org/​10.​1001/​jama.​2020.​17021. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the coDEX randomized clinical trial. JAMA. 2020;324:1307–16. https://​doi.​org/​10.​1001/​jama.​2020.​17021.
20.
Zurück zum Zitat Writing Committee for the REMAP-CAP Investigators, Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324:1317–29. https://​doi.​org/​10.​1001/​jama.​2020.​17022. Writing Committee for the REMAP-CAP Investigators, Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324:1317–29. https://​doi.​org/​10.​1001/​jama.​2020.​17022.
21.
Zurück zum Zitat Prado-Jeronimo CM, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2020. https://​doi.​org/​10.​1093/​cid/​ciaa1177. Prado-Jeronimo CM, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2020. https://​doi.​org/​10.​1093/​cid/​ciaa1177.
22.
Zurück zum Zitat WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330–41. https://​doi.​org/​10.​1001/​jama.​2020.​17023. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330–41. https://​doi.​org/​10.​1001/​jama.​2020.​17023.
23.
Zurück zum Zitat Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980. CrossRef Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980. CrossRef
24.
Zurück zum Zitat Wasmann KA, Wijsman P, van Dieren S, Bemelman W, Buskens C. Partially randomised patient preference trials as an alternative design to randomised controlled trials: systematic review and meta-analyses. BMJ Open. 2019;9:e31151. CrossRef Wasmann KA, Wijsman P, van Dieren S, Bemelman W, Buskens C. Partially randomised patient preference trials as an alternative design to randomised controlled trials: systematic review and meta-analyses. BMJ Open. 2019;9:e31151. CrossRef
25.
Zurück zum Zitat Kowalski CJ. When ethics precludes randomization: put prospective, matched-pair observational studies to work. Perspect Biol Med. 2013;56:184–97. CrossRef Kowalski CJ. When ethics precludes randomization: put prospective, matched-pair observational studies to work. Perspect Biol Med. 2013;56:184–97. CrossRef
28.
Zurück zum Zitat Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198. CrossRef Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198. CrossRef
29.
Zurück zum Zitat Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-coV‑2 admitted to ICus of the Lombardy region, Italy. JAMA. 2020;323:1574–81. CrossRef Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-coV‑2 admitted to ICus of the Lombardy region, Italy. JAMA. 2020;323:1574–81. CrossRef
30.
Zurück zum Zitat Halpern SD, Karlawish JHT, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA. 2002;288:358–62. CrossRef Halpern SD, Karlawish JHT, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA. 2002;288:358–62. CrossRef
Metadaten
Titel
Methylprednisolone in adults hospitalized with COVID-19 pneumonia
An open-label randomized trial (GLUCOCOVID)
verfasst von
Luis Corral-Gudino
Alberto Bahamonde
Francisco Arnaiz-Revillas
Julia Gómez-Barquero
Jesica Abadía-Otero
Carmen García-Ibarbia
Víctor Mora
Ana Cerezo-Hernández
José L. Hernández
Graciela López-Muñíz
Fernando Hernández-Blanco
Jose M. Cifrián
Jose M. Olmos
Miguel Carrascosa
Luis Nieto
María Carmen Fariñas
José A. Riancho
GLUCOCOVID investigators
Publikationsdatum
03.02.2021
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 7-8/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-020-01805-8